ECO Animal Health Group PLC
LSE:EAH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (5.9), the stock would be worth GBX42.3 (55% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13 | GBX94 |
0%
|
| 3-Year Average | 5.9 | GBX42.3 |
-55%
|
| 5-Year Average | 8.1 | GBX58.75 |
-38%
|
| Industry Average | 0 | GBX0.23 |
-100%
|
| Country Average | 0 | GBX0.27 |
-100%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
E
|
ECO Animal Health Group PLC
LSE:EAH
|
63.7m GBP | 13 | 21.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 143.1 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 28.9 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 35.5 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 19.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 24.7 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 43.5 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 22.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 11.6 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 344.9 |
Other Multiples
ECO Animal Health Group PLC
Glance View
ECO Animal Health Group Plc engages in the development, registration and marketing of pharmaceutical products for animals. The company is headquartered in New Malden, Surrey and currently employs 207 full-time employees. The firm's segments include UK, China and Japan, North America, South and South East Asia, Latin America, Europe and the Rest of the World. The firm's principal activity is the manufacture and supply of animal health products across the globe. These activities are conducted on a global scale, through a network, including both regional offices (notably in Shanghai and Princeton) and overseas subsidiaries. Its products include Aivlosin, Ecomectin and others. Aivlosin is a macrolide antibiotic for treatment of respiratory and enteric diseases in pigs and poultry. Ecomectin is an endectocide that controls worms, ticks, lice and mange in grazing stock and pigs. Its Ecoheart, Ecotraz and Ecomintic are for the treatment and prevention of parasites in cattle, sheep, pigs, horses and dogs.
